Glofitamab plus R-ICE chemotherapy in R/R DLBCL: a Phase Ib study

Catherine Diefenbach, MD, NYU Langone, New York City, NY, comments on the results of a Phase Ib study (NCT05364424) evaluating the combination of glofitamab with rituximab and ifosfamide, carboplatin, and etoposide (R-ICE) chemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Diefenbach highlights the combination's favorable efficacy and manageable safety profile, with an overall response rate exceeding 80%. This combination may offer a promising second-line treatment option to optimally prepare patients for autologous stem cell transplant or CAR T-cell therapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.